Please login to the form below

Not currently logged in
Email:
Password:

Kalina Scott joins Switzerland's Polyphor

Moves from Bank am Bellevue to take up CFO role at the pharma company

Switzerland-based pharmaceutical company Polyphor has appointed Kalina Scott as its chief financial officer.

She has over 20 years’ experience in mergers, acquisitions, capital markets and private placements particularly in the healthcare field, and has joined the privately-owned company from Bank Am Bellevue where she served as managing director.

She said: “I am honoured and very excited about the opportunity to support Polyphor in its goal to become the leader in the development of powerful therapies that help patients to improve their lives and bring value to shareholders.”

During her career Scott has worked with a number of corporate companies and medical groups including Molecular Partners, Cassiopea, Galenica Santé, Mathys Medical and Sulzer Medica.

Giacomo Di Nepi, CEO of Polyphor, said: “I am very pleased that Kalina has decided to join Polyphor.

“Her extensive experience in the finance area, combined with her transaction-based expertise in healthcare and her broad network will help grow Polyphor and support our corporate strategy and transformation.”

Scott succeeds Alain Schaffter who will leave Polyphor to take on a what the company said would be a new challenge.

7th June 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics